MEVAC the pride of global vaccine industry
Poultry Vaccines: Avian Influenza (H5N1, H5N8), Newcastle Disease, Infectious Bronchitis, Fowl Adenovirus
Ruminant Vaccines: Foot-and-Mouth Disease (FMD), Lumpy Skin Disease (LSD)
Aquaculture Vaccines: Fish Vaccines
Human Vaccines: Measles, Rubella, Rotavirus (under development)
Middle East for Vaccines (MEVAC) is a pioneering biotechnology company based in Cairo, Egypt, specializing in the research, development, and manufacturing of veterinary and human vaccines. As the first private-sector company in the Middle East and Africa to produce avian influenza vaccines, MEVAC plays a strategic role in enhancing regional biosecurity and food safety.
Established in 2009, MEVAC was formed as a response to the urgent need for domestic vaccine production following avian influenza outbreaks in the region. Since its inception, the company has grown rapidly, supported by the Arab Authority for Agricultural Investment and Development (AAAID) and strategic partnerships with international research organizations.
MEVAC’s core business lies in the production of high-quality vaccines for poultry, ruminants, aquaculture, and, more recently, humans. The company combines advanced virology, immunology, and biotechnology to deliver customized vaccination solutions that address regional disease challenges.
MEVAC also offers contract manufacturing services, diagnostic testing, and technical consultation for vaccine application and disease control strategies.
MEVAC is renowned for its region-specific vaccine formulations, designed to combat endemic diseases affecting local poultry and livestock. Its avian influenza vaccines, branded as MEFLUVAC, are recognized for their efficacy and have been widely used across the Middle East and North Africa. The company is unique in combining R&D, manufacturing, and field diagnostics under one roof, allowing rapid response to emerging health threats.
Though privately held, MEVAC’s expansion has been driven by significant investment from AAAID and other stakeholders. The company operates a state-of-the-art facility in Cairo with scalable production lines capable of delivering millions of vaccine doses annually. Its revenue growth is linked to strong demand in both domestic and export markets, driven by government and private sector biosecurity initiatives.
MEVAC exports to over 20 countries in the Middle East, Africa, and Asia. Its poultry vaccines, particularly those for avian influenza and Newcastle Disease, are highly sought after in Gulf markets. Import-export platforms like Trademo and Volza have recorded recurring shipment volumes of MEVAC vaccines to Saudi Arabia, Sudan, and Pakistan, among others, indicating its strong regional penetration.
MEVAC’s primary clients include:
MEVAC complies with:
Customers consistently highlight MEVAC’s responsiveness, product reliability, and expert field support. Its avian influenza and FMD vaccines have been praised by regional veterinary authorities for their performance during outbreaks, with testimonials often cited during national health conferences and agriculture expos.
MEVAC continues to lead Egypt and the region in biotech innovation, offering robust solutions for zoonotic and animal diseases while actively working toward human vaccine production to enhance global health resilience.
